Total Payments
$43,088
2024 Payments
$16,425
Companies
1
Transactions
9
Payment Breakdown by Category
Research$43,088 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43,088 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $43,088 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,425 | 3 | ABBVIE INC. ($16,425) |
| 2023 | $16,088 | 3 | AbbVie Inc. ($16,088) |
| 2022 | $10,575 | 3 | ABBVIE INC. ($10,575) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | ABBVIE INC. | QULIPTA (Drug) | — | Cash or cash equivalent | $3,600.00 | Research |
| Study: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine • Category: NEUROSCIENCE | ||||||
| 04/22/2024 | ABBVIE INC. | UBRELVY (Drug) | — | Cash or cash equivalent | $8,100.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) • Category: NEUROSCIENCE | ||||||
| 04/22/2024 | ABBVIE INC. | QULIPTA (Drug) | — | Cash or cash equivalent | $4,725.00 | Research |
| Study: A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Episodic Migraine • Category: NEUROSCIENCE | ||||||
| 11/01/2023 | AbbVie Inc. | UBRELVY (Drug) | — | Cash or cash equivalent | $6,862.50 | Research |
| Study: A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions • Category: NEUROSCIENCE | ||||||
| 07/26/2023 | AbbVie Inc. | QULIPTA (Drug) | — | Cash or cash equivalent | $5,175.00 | Research |
| Study: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine • Category: NEUROSCIENCE | ||||||
| 07/05/2023 | AbbVie Inc. | UBRELVY (Drug) | — | Cash or cash equivalent | $4,050.00 | Research |
| Study: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants (UBR Prodrome) • Category: NEUROSCIENCE | ||||||
| 12/08/2022 | ABBVIE INC. | UBRELVY (Drug) | — | Cash or cash equivalent | $3,600.00 | Research |
| Study: Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome • Category: NEUROSCIENCE | ||||||
| 12/08/2022 | ABBVIE INC. | UBRELVY (Drug) | — | Cash or cash equivalent | $3,600.00 | Research |
| Study: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants • Category: NEUROSCIENCE | ||||||
| 05/19/2022 | ABBVIE INC. | UBRELVY (Drug) | — | Cash or cash equivalent | $3,375.00 | Research |
| Study: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants • Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | ABBVIE INC. | $8,100 | 1 |
| Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants | ABBVIE INC. | $6,975 | 2 |
| A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions | AbbVie Inc. | $6,863 | 1 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | AbbVie Inc. | $5,175 | 1 |
| A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Episodic Migraine | ABBVIE INC. | $4,725 | 1 |
| Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants (UBR Prodrome) | AbbVie Inc. | $4,050 | 1 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | ABBVIE INC. | $3,600 | 1 |
| Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome | ABBVIE INC. | $3,600 | 1 |
About Dr. Gerry Gerry, M.D
Dr. Gerry Gerry, M.D is a Pediatrics healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831296037.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerry Gerry, M.D has received a total of $43,088 in payments from pharmaceutical and medical device companies, with $16,425 received in 2024. These payments were reported across 9 transactions from 1 company. The most common payment nature is "" ($43,088).
Ad
Practice Information
- Specialty Pediatrics
- Location Kansas City, MO
- Active Since 09/20/2006
- Last Updated 07/30/2015
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1831296037
Products in Payments
- UBRELVY (Drug) $29,588
- QULIPTA (Drug) $13,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Kansas City
Wendy Hein, Rn, Cpnp, RN, CPNP
Pediatrics — Payments: $261,007
Pediatrics $261,007
Dr. Ryan Fischer, Md, MD
Pediatrics — Payments: $151,757
Pediatrics $151,757
Dr. Ryan Mcdonough, Do, DO
Pediatrics — Payments: $131,848
Pediatrics $131,848
Terri Luetjen, Rn, Cpnp, RN, CPNP
Pediatrics — Payments: $57,452
Pediatrics $57,452
Dr. Sharon Humiston, M.d, M.D
Pediatrics — Payments: $43,734
Pediatrics $43,734
Laurel Willig, Md, MD
Pediatrics — Payments: $19,655
Pediatrics $19,655